Research Development - Editas Medicine Inc (NASDAQ:EDIT) - Alpha Spread

First Time Loading...

Watchlist Manager

Watchlist

Price: 5.37 USD 3.07%

Updated:

Editas Medicine Inc
Research & Development

Last Value

3-Years 3-Y CAGR

5-Years 5-Y CAGR

10-Years 10-Y CAGR

Quarterly

Annual

TTM

|

Adjust for Inflation

Editas Medicine Inc
Research & Development Peer Comparison

ABBV

GILD

AMGN

VRTX

REGN

Company		Research & Development	CAGR 3Y	CAGR 5Y	CAGR 10Y
	Editas Medicine Inc NASDAQ:EDIT	Research & Development -$177.7m	CAGR 3-Years -4%	CAGR 5-Years -14%	CAGR 10-Years N/A
	Abbvie Inc NYSE:ABBV	Research & Development -$7B	CAGR 3-Years -4%	CAGR 5-Years -6%	CAGR 10-Years -9%
	Gilead Sciences Inc NASDAQ:GILD	Research & Development -$5.7B	CAGR 3-Years 19%	CAGR 5-Years -3%	CAGR 10-Years -10%
	Amgen Inc NASDAQ:AMGN	Research & Development -$4.8B	CAGR 3-Years -4%	CAGR 5-Years -5%	CAGR 10-Years -2%
	Vertex Pharmaceuticals Inc NASDAQ:VRTX	Research & Development -$3.7B	CAGR 3-Years -26%	CAGR 5-Years -21%	CAGR 10-Years -15%
	Regeneron Pharmaceuticals Inc NASDAQ:REGN	Research & Development -$4.4B	CAGR 3-Years -18%	CAGR 5-Years -15%	CAGR 10-Years -18%

See Also

Based on the financial report for Dec 31, 2023, Editas Medicine Inc's Research & Development amounts to -177.7m USD.

Over the last year, the Research & Development growth was -2%. The average annual Research & Development growth rates for Editas Medicine Inc have been -4% over the past three years , -14% over the past five years .

Join more than 133,300+ value investors using Alpha Spread

Create a free account

or see our plans & pricing

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

What is Intrinsic Value? Help Center Contact Us

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.